Introduction
Preterm delivery is the most common cause of neonatal morbidity and mortality [1] [2] [3] . Since preterm contractions correlate highly with preterm delivery, their inhibition by tocolysis constitutes a major element in the corresponding treatment [4] . Beta-adrenergic receptor agonists, nifedipine and atosiban, are the main drugs for the pharmacological therapy of preterm contractions [4, 5] .
The usage of Bryophyllum pinnatum, a herbal medication traditionally used in anthroposophic medicine, as a tocolytic was established in 1970 [6, 7] . Retrospective analyses revealed good effectiveness and very good tolerability in patients treated with B. pinnatum preparations [8, 9] and a matched-pairs study corroborated these results [10] . More recently, an observational study was performed [11] . The use of B. pinnatum as a tocolytic agent is supported by experimental evidence [12] . The available evidence demanded prospective, randomised trials to characterise efficacy. Here, 2 trials are described which were initiated independently to fill in this knowledge gap.
Patients and Methods
Both studies were approved by the local ethics committees (Trial I, Basel; Trial II, Zurich) and performed in accordance with the Declaration of Helsinki. All patients signed an informed consent form. In both trials, the number of recruited patients was markedly lower than the numbers determined in the power analysis; therefore, results are presented descriptively only. B. pinnatum preparations used in both trials were manufactured by Weleda AG, Arlesheim, Switzerland, according to Good Manufacturing Practice and with plant leaves provided by Weleda, Brazil (voucher specimen no. ZSS 29717 deposited at the Zurich Succulent Plant Collection, Switzerland). The preparations are registered in Switzerland without indication and are defined based on manufacturing procedures and specifications (mother tincture according to method 1.1.7. of the European Pharmacopoeia). Two classes of compounds from B. pinnatum leaves have so far been investigated in detail, the flavonoid glycosides and the bufadienolides [13] .
Trial I (NCT00163579) was a prospective, randomised, double-blind, placebo-controlled, investigator-initiated clinical trial and started at Basel Women's University Hospital (UFK). The aim of the trial was to investigate the efficacy of B. pinnatum in the prophylaxis of preterm birth. The study was approved by Swiss Agency for therapeutic products (Swissmedic) and ran from February 2004 until April 2008. Women presenting with singleton pregnancies and at high risk of developing preterm contractions (e.g., prior preterm delivery, prior preterm contractions or prior cerclage) or with multiple pregnancies were recruited, if they did not fulfil the following exclusion criteria: age under 18 years, Body Mass Index 30, foetal malformations known at the time of recruitment and intrauterine growth restriction. The randomisation of the 2 groups was performed using program Z by the hospital pharmacy and took place after the 26th gestational week. Study medication was B. pinnatum 33% tincture (33% of fresh plant with 45% ethanol w/w; final ethanol content 36% v/v; DEV 0.04: 1, i.e., 40 mg dried B. pinnatum matter in 1 g mother tincture). The hospital pharmacy of the University Hospital Basel produced the placebo solution (1% ferric chloride solution, similar mixture of ethanol and water). Pregnant women received 20 drops 5 times a day of either B. pinnatum tincture 33% or placebo (i.e., maximal ethanol doses per day 0.96 g). In the cases in which these treatments were not efficiently preventing preterm painful contractions (no additional criterion), participants received standard tocolysis with or without lung maturation. The main outcome was pregnancy duration. The power was calculated to be approximately 80% with a detectable difference of 10 days and a sample size of 30 (per group, for each of the 3 initial hypotheses) with a standard deviation of 2 weeks.
Trial II (NCT00391339 [14] ) was a prospective, controlled, open-labelled randomised, clinical trial initiated at the University Hospital Zurich and sponsored by Weleda AG. The aim of this study with a parallel design was to compare efficacy and safety of B. pinnatum 50% tablets and nifedipine in tocolysis.
All study documents were approved by Swissmedic. The study ran from December 2006 until November 2009. In-and outpatients were included based on the following criteria: single pregnancy, gestational age < 34 weeks and 1 day, indication for loading treatment with nifedipine due to premature labour, Bishop score < 5, negative fibronectin test, lack of vaginal bleeding, no contraindication for nifedipine or B. pinnatum, no drug abuse, no participation in another trial in the last 4 weeks. Study medication was B. pinnatum 50% as chewable tablets (each 350 mg tablet corresponds to 170 mg of leave press juice, dried down to 17 mg by mixing with lactose; 100 mg dried B. pinnatum matter in 1 g). Nifedipine, a standard medication at the University Hospital Zurich, Hospitalisation, n 8 b Missing values B. pinnatum group (placebo group) for gestational age at study end, n = 1 (n = 1) in the singleton subgroup and n = 2 (n = 1) in the multiple subgroup. Missing values for treatment duration or values excluded due to low compliance in the B. pinnatum group (and placebo group): singleton subgroup n = 1 (n = 3), multiple group n = 2 (n = 3). c twins, n = 3; triplets, n = 2. d twins, n = 8. NICU = neonatal intensive care unit. 9.1 ± 0.7 9.1 ± 0.7 10'
9.3 ± 0.5 9.3 ± 0.5 a Data are shown either as mean ± standard deviation or as number of patients.
b Missing values B. pinnatum group: pulse at baseline examination, n = 3; blood pressure systolic and diastolic at 3rd examination, n = 1; pulse at 3rd examination, n = 2. c Missing values nifedipine group: blood pressure at baseline examination, n = 1; pulse at baseline examination, n = 2; pulse and blood pressure at 1 st examination, n = 1; CTG, Bishop score and adverse reactions at 2 nd examination, n = 1; pulse and blood pressure at 2 nd examination, n = 2; haematological parameters at 3 rd examination, n = 1; pulse and blood pressure at 3 rd examination, n = 2; all values at the 4 th examination, n = 1. d Several reactions possible. ALT = alanine aminotransferase; AST = aspartate aminotransferase; bpm = beats per minute; BPS = blood pressure systolic; BPD = blood pressure diastolic; CRP = C-reactive protein; CTG = cardiotocography. After 1 h and 15 min, they were given an Adalat CR ® 60 mg tablet. Afterwards, patients received an Adalat CR ® 60 mg or Adalat CR ® 30 mg tablet alternately every 12 h over the following 48 h. The main outcome was the difference in patients' response to tocolysis (contraction frequency had decreased, or contraction frequency had not decreased, but the Bishop score was <5) between the 2 groups. For this one-sided equivalence test, results for the main outcome parameter with power 90% and significance level alpha = 0.05 lead to an estimated number of required 69 patients per study group. Thereby, a success rate of nifedipine of 80% and a detectable minimum success rate of 60% in the B. pinnatum group were assumed. Because of possible dropouts, the effectively required number of patients was increased to 70 per group.
Results

Trial I
For this section, see table 1. At study discontinuation, 26 pregnant women had been recruited. Duration of pregnancy was comparable in the groups with and without B. pinnatum. All patients were hospitalised and received additional tocolysis (atosiban, hexoprenalin, indomethacine, nifedipine and oral magnesium salt); one patient of the B. pinnatum group was additionally given progesterone. In the B. pinnatum group, most patients were treated with hexoprenalin and nifedipine (5/13), with hexoprenalin alone (3/13) or with nifedipine alone (2/13). In the placebo group, most patients were treated with hexoprenalin alone (8/13) or with atosiban (2/13). No serious adverse drug reactions occurred during this study. In the B. pinnatum group, 1 newborn had a pathological genetic analysis (Factor V Leiden thrombophilia); no perinatal deaths occurred.
Trial II For this section, see table 2. The study was stopped prematurely when 27 patients had been recruited. Both groups were comparable at baseline, except that patients of the B. pinnatum group were on average 2 years older at recruitment than patients from the nifedipine group (32.9 vs. 30.9 years). A comparable decrease in contraction frequency from the baseline examination to the examination after 4 h of treatment was observed in the 2 groups. The tolerability of the therapy was documented after 4 h as very good in 9 cases of the B. pinnatum group (good: n = 5; moderate: n = 0) and in 1 case of the nifedipine group (good: n = 8; moderate: n = 3). In addition, after 49 h the tolerability was also very good in 9 cases of the B. pinnatum group (good: n = 5) and in 1 case of the nifedipine group (good: n = 8; moderate: n = 2; poor: n = 1). Alanine aminotransferase, aspartate aminotransferase and C-reactive protein values were comparable in the various examinations and in the 2 groups. No serious adverse events happened during the study.
Discussion
In the last decade, B. pinnatum began to be used at university institutions in Switzerland, where at present it constitutes an inherent part of the standard preterm contractions treatment (see [15] ). The relatively low evidence level on which this use of B. pinnatum is based, together with the lack of fully efficacious and well-tolerated synthetic, tocolytic agents, makes the performance of randomised controlled trials urgent. Given the low number of patients who could be recruited in the 2 trials described here, no definitive conclusions on efficacy and safety are possible, although some results are promising for subsequent studies. This manuscript should be seen mainly as a contribution to bias reduction in clinical research.
Poor recruitment rate is the most common reason for trial discontinuation [16, 17] and should be reported and discussed. In the case of the present studies, the difficulties inherent in carrying out clinical trials with pregnant women are likely to have contributed to the severe delay in patient recruitment. The previous use of B. pinnatum preparations by several screened patients at study initiation might have played a role, as well as the low budgets. Although trials I and II reveal the willingness of Swiss university institutions to investigate promising herbal products, the faced difficulties must be avoided in the future. For this purpose, enhanced financial and human resources for future randomised clinical trials are urgently needed.
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